| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3810/PGM.2010.01.2111 |
| P8608 | Fatcat ID | release_ygb6ykrklbgabarit5kshfndqy |
| P698 | PubMed publication ID | 20107301 |
| P2093 | author name string | Thomas Blevins | |
| P2860 | cites work | Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association | Q22241916 |
| Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 | ||
| Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
| One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial | Q28277510 | ||
| Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses | Q28285795 | ||
| Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr | Q33279692 | ||
| Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects | Q33441916 | ||
| Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) | Q33854032 | ||
| Metabolic consequences of weight loss on glucose metabolism and insulin action in type 2 diabetes | Q34163365 | ||
| Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity | Q34416085 | ||
| The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the United States. | Q51127959 | ||
| Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. | Q51469774 | ||
| Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. | Q51471806 | ||
| The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. | Q51473976 | ||
| A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. | Q51483637 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. | Q51483804 | ||
| Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. | Q51483830 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Q51484788 | ||
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | Q51484798 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | Q51489068 | ||
| Intensive glycemic control in the ACCORD and ADVANCE trials | Q53654194 | ||
| Biological specificity of visceral adipose tissue and therapeutic intervention | Q58457087 | ||
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study | Q34598940 | ||
| The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone | Q34608300 | ||
| Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes | Q34835217 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies | Q35559800 | ||
| Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri | Q35847375 | ||
| Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease | Q36015883 | ||
| Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm | Q36258154 | ||
| Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus | Q36407215 | ||
| Management of Type 2 diabetes: the role of incretin mimetics | Q36613938 | ||
| Weight change in diabetes and glycemic and blood pressure control | Q36906205 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study | Q36975695 | ||
| Standards of medical care in diabetes--2009. | Q37036416 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors | Q37160663 | ||
| Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease | Q37198072 | ||
| Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus | Q37215415 | ||
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Q37235840 | ||
| Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-b | Q37235875 | ||
| Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes | Q37319183 | ||
| Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis | Q37400779 | ||
| Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card | Q41824843 | ||
| Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes | Q42165729 | ||
| Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes | Q42169660 | ||
| Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes | Q43299560 | ||
| Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding | Q43869418 | ||
| Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial | Q44333538 | ||
| Exenatide use in the management of metabolic syndrome: a retrospective database study | Q44479185 | ||
| Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects | Q44779248 | ||
| Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients | Q44848283 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial | Q46344895 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes | Q46691051 | ||
| Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis | Q46792787 | ||
| Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes | Q46804059 | ||
| Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial | Q46834147 | ||
| Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin | Q47274492 | ||
| Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus | Q47333601 | ||
| Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). | Q50110246 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 172-183 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Postgraduate Medicine | Q7234297 |
| P1476 | title | Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes | |
| P478 | volume | 122 |
| Q37750274 | Managing type 2 diabetes: balancing HbA1c and body weight |
| Q93147542 | Preclinical and Clinical Evidence for a Distinct Regulation of Mu Opioid and Type 1 Cannabinoid Receptor Genes Expression in Obesity |
| Q42171281 | Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors |
Search more.